AdrianMSenderowiczMD

PubMed

• 17 citations
  Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with p...
  Andrew D.J. Pearson, Kimberly Stegmaier, Franck Bourdeaut, Gregory H. Reaman, Delphine Heenen, Michael L. Meyers, Scott A. Armstrong, Patrick A. Brown, Daniel D. De Ca...> ;European Journal of Cancer. 2020 Nov 1
• 41 citations
  A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
  Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, J.-L. Lee, Bhumsuk Keam, Sun Young Rha, Ulka N. Vaishampayan, W. B. Harris, Stephen Lane Richey, J. M. Randall, Da...> ;Annals of Oncology. 2017 Nov 1
• 14 citations
  A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms
  William D. Figg, Manish Monga, Donna Headlee, Avni A. Shah, Cindy H. Chau, Cody J. Peer, Richard Messman, Yusri A. Elsayed, Anthony J. Murgo, Giovanni Melillo, Qin C. ...> ;Cancer Chemotherapy and Pharmacology. 2014 Sep 3
• 21 citations
  Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics
  Adrian M. Senderowicz, Otmar Pfaff> ;Clinical Cancer Research. 2014 Mar 15
• 130 citations
  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
  Edward A. Sausville, Patricia LoRusso, Michael A. Carducci, Judith Carter, Mary F. Quinn, Lisa Malburg, Nilofer S. Azad, David Cosgrove, Richard Knight, Peter Barker, ...> ;Cancer Chemotherapy and Pharmacology. 2014 Jan 22
• Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
  Sausville EA, LoRusso P, Carducci MA, Barker PN, Agbo F, Oakes P, Senderowicz AM> ;J. Clin. Oncol.. 2011-05-20
• Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
  Ho AL, Bendell JC, Cleary JM, Schwartz GK, Burris HA, Oakes P, Agbo F, Barker PN, Senderowicz AM, Shapiro G> ;J. Clin. Oncol.. 2011-05-20
• 25 citations
  Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer
  Adrian M. Senderowicz> ;Clinical Cancer Research. 2010 Mar 15
• 8 citations
  Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b)
  Paola Rojas, Fernando Benavides, Jorge Blando, Kim Cardenas, Ellen R. Richie, Erik S. Knudsen, David G. Johnson, Adrian M. Senderowicz, Marcelo L. Rodriguez-Puebla, Cl...> ;Molecular Carcinogenesis. 2009 Jun 1
• 13 citations
  CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development.
  Everardo Macias, Paula L. Miliani de Marval, Adriana De Siervi, Claudio J. Conti, Adrian M. Senderowicz, Marcelo L. Rodriguez-Puebla> ;The American Journal of Pathology. 2008 Aug 1
• 39 citations
  S-Phase-specific Activation of PKCα Induces Senescence in Non-small Cell Lung Cancer Cells
  José Luis Oliva, M. Cecilia Caino, Adrian M. Senderowicz, Marcelo G. Kazanietz> ;The Journal of Biological Chemistry. 2008 Feb 29
• 48 citations
  Erlotinib/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Adenocarcinoma of the Pancreas
  Senderowicz Am, Johnson, Rajeshwari Sridhara, Zimmerman P, Robert Justice, Richard Pazdur> ;Oncology. 2007 Dec 1
• An analysis of deficiencies identified during investigational new drug (IND) application reviews by the Division of Drug Oncology Products (DDOP) of the US FDA.
  Mann BS, Kane R, Brave M, Ryan Q, Hazarika M, Rock E, Senderowicz A, Dagher R, Johnson J, Justice R, Pazdur R> ;J. Clin. Oncol.. 2006-06-20
• 66 citations
  Inhibition of CDKs as a Therapeutic Modality
  Edward A. Sausville, Jill R. Johnson, Michael C. Alley, Daniel W. Zaharevitz, Adrian M. Senderowicz> ;Annals of the New York Academy of Sciences. 2006 Jan 25
• 38 citations
  Inhibitors of cyclin-dependent kinase modulators for cancer therapy
  Adrian M. Senderowicz> ;Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques. 2005 Jan 1
• 55 citations
  Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1
  Martin F. Aguero, Maria Marta Facchinetti, Zhanna Sheleg, Adrian M. Senderowicz> ;Cancer Research. 2005 Apr 15
• 45 citations
  RNA Silencing of Checkpoint Regulators Sensitizes p53-Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells
  Utpal K. Mukhopadhyay, Adrian M. Senderowicz, Gerardo Ferbeyre> ;Cancer Research. 2005 Apr 1
• 1 citations
  Role of cell cycle control and cyclin-dependent kinases in breast cancer.
  Adrian M. Senderowicz> ;Breast Disease. 2002 Jan 1
• 84 citations
  Targeting cell cycle and apoptosis for the treatment of human malignancies
  Adrian M. Senderowicz> ;Current Opinion in Cell Biology. 2004 Dec 1
• 20 citations
  Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine
  Alex Sparreboom, Huachen Chen, Milin Acharya, Adrian M. Senderowicz, Richard A. Messmann, Takashi Kuwabara, David Venzon, Anthony J. Murgo, Donna Headlee, Edward A. Sa...> ;Clinical Cancer Research. 2004 Oct 15
• 43 citations
  UCN-01-Induced Cell Cycle Arrest Requires the Transcriptional Induction of p21waf1/cip1 by Activation of Mitogen-Activated Protein/Extracellular Signal-Regulated Kinas...
  Maria Marta Facchinetti, Adriana De Siervi, Doreen Toskos, Adrian M. Senderowicz> ;Cancer Research. 2004 May 15
• 7 citations
  Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.
  Birgit Hagenauer, Alexandra Maier-Salamon, Theresia Thalhammer, Peter Zöllner, Adrian M. Senderowicz, Walter Jäger> ;Oncology Reports. 2004 May 1
• 14 citations
  Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
  Anita F.W. Frijhoff, Claudio J. Conti, Adrian M. Senderowicz> ;Molecular Carcinogenesis. 2004 Apr 1
• 59 citations
  Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/c...
  Adriana De Siervi, Maria Marinissen, Jessica Diggs, Xiao-Fan Wang, Gilles Pagès, Adrian M. Senderowicz> ;Cancer Research. 2004 Jan 15
• 3 citations
  Assays for cyclin-dependent kinase inhibitors.
  Adrian M. Senderowicz> ;Methods in Molecular Biology. 2004 Jan 1
• Join now to see all

Abstracts/Posters

• Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor...
  Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...
  Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019